Highlights Pulmatrix, Inc.

Equities

PULM

US74584P3010

Delayed Nasdaq Other stock markets 12:50:35 14/05/2024 am IST			5-day change	1st Jan Change
1.78 ^USD	0.00%		-4.30%	-4.30%

10/05	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/05	Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M	10/05	MT
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives	08/01	DJ
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis	08/01	CI
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M	09/11	MT
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23/23/23	CI
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M	10/23/10	MT
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine	11/23/11	CI
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $1.5M	12/23/12	MT
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis in Subjects with Asthma	06/23/06	CI
Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine, for Acute Migraine	04/23/04	CI
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.9M	10/22/10	MT
Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine	26/22/26	CI
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pulmatrix, Inc.

Equities

PULM

US74584P3010

Highlights

Filters